TD Cowen analyst Tyler Van Buren raised the firm’s price target on Gilead (GILD) to $125 from $115 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results while increasing their total liver and Trodelvy estimates while decreasing total cell therapy and Veklury.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead terminated Phase 1 study of ‘1219, says RBC Capital
- Galapagos price target raised to $28 from $27 at RBC Capital
- Galapagos intends to wind down cell therapy business
- Gilead Sciences Completes Promising Study on Metastatic Colorectal Cancer Treatment
- Gilead, AstraZeneca, and Roche Data Signal New Growth in Cancer Drug Market